Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMTMI + Fludarabine/Melphalan for Allogeneic Transplantation in Advanced Hematologic Malignancies
NCT02333162Phase 1Suspended
- Sponsor
- University of Chicago
- Start
- Dec 2014
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in hematologic malignancy, sponsored by University of Chicago. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Dec 2014; status: suspended.
02
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02333162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02333162.